Resource Use and Costs Related to Hematological Complications of Chemotherapy: Cost of Illness Study Based on Data from Balkan Country with Recent History of Socioeconomic Transition
Background: The administration of chemotherapy positively correlates with diverse adverse drug reactions, including the significant impact of hematological hazards such as anemia, leukopenia-neutropenia, thrombocytopenia, and pancytopenia. This pilot pharmacoeconomic study aimed to estimate the total direct costs of treating hematological toxicity induced by chemotherapy and its main determinants.
Methods: The study was conducted as a retrospective cost of illness study using the ''from bottom to the top'' approach from the perspective of the Republic Health Insurance Fund. This study included 88 patients treated due to developing at least one episode of one of the types of hematological complications of cytostatics in 2018 at the Oncology Clinic of the University Clinical Center Kragujevac, Kragujevac, the Republic of Serbia.
Results: Among cancer patients who developed haematological toxicity, treating pancytopenia was most demanding in a pharmacoeconomic manner compared to neutropenia and thrombocytopenia, with an estimated value of direct costs of 264,14, 178,19 and 157,76 euros per patient per year respectively. Regarding total direct costs, the main determinants were the costs of drugs, their parenteral administration, and costs due to hospitalization.
Conclusion: Due to the rising cancer incidence and obligatory hospital treatment of hematological toxicity induced by chemotherapy, the identification of the pharmacoeconomic aspects of the treatment of these complications is needed. Future research should focus on the development of new modalities of treatment regarding patient characteristics anticipating high costs.
2. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW (2007). Eco-nomic burden of haematological adverse effects in cancer patients: a systematic re-view. Clin Drug Investig, 27(6):381-96.
3. Cremieux PY, Slavin MB, Fendrick M, Hiriak TC (2002). The costs of cancer: cancer-related conditions can add dra-matically to overall costs of care. J Man-aged Care Med, 6:12–19.
4. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103(9):1916-24.
5. Donohue R (2006). Development and im-plementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncol Forum, 33 (2): 347-52.
6. Onuoha C, Arshad J, Astle J, Xu M, Halene S (2016). Novel Developments in Leuko-penia and Pancytopenia. Prim Care, 43(4):559-73.
7. Family L, Xu L, Xu H, et al (2016). The ef-fect of chemotherapy-induced anemia on dose reduction and dose delay. Support Care Cancer, 24(10):4263-71
8. Gauer RL, Braun MM (2012). Thrombocy-topenia. American Family Physician, 85(6):612-22.
9. Hashiguchi Y, Fukuda T, Ichimura T, et al (2015). Chemotherapy-induced thrombo-cytopenia and clinical bleeding in patients with gynecologic malignancy. Eur J Gynae-col Onco, 36(2):168-73.
10. Husereau D, Drummond M, Petrou S, et al (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ, 14(3):367-72.
11. Janković SM (2016). Dizajn istraživanja. 1st ed.. Kragujevac: Medicinsko društvo za racionalnu terapiju Republike Srbije – Medrat.
12. Mayordomo JI, López A, Viñolas N, et al (2009). Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin, 25(10):2533-42.
13. Republički fond za zdravstveno osiguranje (2021). Pravilnik o cenama zdravstvenih usluga na sekundarnom i tercijarnom nivou zdravstvene zaštite. https://www.pravno-informacioni-sis-tem.rs/SlGlasnikPortal/eli/rep/sgrs/drugidrzavniorganiorganizaci-je/pravilnik/2022/47/1
14. Republički fond za zdravstveno osiguranje (2014). Tarifna knjiga zdravstvenih usluga u zdravstvenim ustanovama Re-publike Srbije. Beograd.
15. IBM Corp. Released 2012. IBM SPSS Statis-tics for Windows, Version 21.0. Armonk, NY: IBM Corp.
16. Catic T, Mekic-Abazovic A, Sulejmanovic S (2016). Cost of febrile neutropenia treat-ment in Bosnia and Herzegovina. Mater Sociomed, 28(2)112-15.
17. Tai E, Guy GP, Dunbar A, Richardson LC (2017). Cost of cancer-related neutro-penia or fever hospitalizations, United States, 2012. J Oncol Pract, 13(6):552- 61. 38.
18. Wang XJ, Wong M, Hsu LY, Chan A (2014). Costs associated with febrile neu-tropenia in solid tumor and lymphoma patients–an observational study in Singa-pore. BMC Health Serv Res, 14(1):434.
19. Copley-Merriman C, Stevinson K, Liu FX, et al (2018). Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine (Baltimore), 97(31): e11736.
20. Elting LS, Cantor SB, Martin CG, et al (2003). Cost of chemotherapy‐induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer: Inter-disciplinary International Journal of the American Cancer Society, 97(6):1541-50.
21. Newburger PE (2016). Autoimmune and other acquired neutropenias. Hematology Am Soc Hematol Educ Program, (1):38-42.
22. Hayat AS, Khan AH, Baloch GH, Shaikh N (2014). Pancytopenia: study for clinical features and etiological pattern at tertiary care settings in Abbottabad. The Profession-al Medical Journal, 21(1):60-5.
23. Haines IE, Olver I (2009). Are guidelines on use of colony‐stimulating factors in solid cancers flawed?. Int Med J, 39(4):259-62
24. Bhatt VR (2019). Cancer in older adults: un-derstanding cause and effects of chemo-therapy-related toxicities. Future Oncol, 15(22):2557-2560.
25. Lyman GH, Berndt ER, Kallich JD, et al (2005). The economic burden of anemia in cancer patients receiving chemothera-py. Value Health, 8(2):149-56.
|Issue||Vol 51 No 11 (2022)|
|Hematological complications Chemotherapy Cost of illness Direct costs Pharmacoeconomics|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|